Search results for "Solid Tumors"

showing 10 items of 41 documents

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Reg…

2015

Background The European Association for the Study of the Liver (EASL) criteria and the modified Response Evaluation Criteria in Solid Tumors (mRECIST) are currently adopted to evaluate radiological response in patients affected by HCC and treated with loco-regional procedures. Several studies explored the validity of these measurements in predicting survival but definitive data are still lacking. Aim To conduct a systematic review of studies exploring mRECIST and EASL criteria usefulness in predictive radiological response in HCC undergoing loco-regional therapies and their validity in predicting survival. Methods A comprehensive search of the literature was performed in electronic database…

OncologyGenetics and Molecular Biology (all)medicine.medical_specialtyCarcinoma HepatocellularPrognosiConcordancePopulationMEDLINElcsh:MedicineCarcinoma Hepatocellular; Humans; Liver Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Cochrane LibraryBiochemistryInternal medicinemedicineHumanseducationlcsh:ScienceSurvival analysiseducation.field_of_studyMultidisciplinaryBiochemistry Genetics and Molecular Biology (all)Carcinoma Hepatocellular; Humans; Liver Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Agricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)business.industryMedicine (all)CarcinomaLiver Neoplasmslcsh:RHepatocellularPrognosisSurvival AnalysisConfidence intervalSurgeryTreatment OutcomeAgricultural and Biological Sciences (all)Response Evaluation Criteria in Solid TumorsLiver NeoplasmMeta-analysislcsh:QSurvival AnalysibusinessHumanResearch ArticlePLoS ONE
researchProduct

Molecular target therapy for bone metastasis : starting a new era with denosumab, a RANKL inhibitor

2014

Abstract: Introduction: The skeleton is generally the primary, and sometimes the only, site of metastasis in patients with advanced solid tumors. Bone metastases are the most frequent cause of cancer-related pain and the origin of severe morbidity in patients. Among the treatment options available for the prevention of skeletal-related events (SREs) associated with bone metastasis, zoledronic acid, an antiresorptive treatment from the group of bisphosphonates, is currently the standard of care in this setting. Areas covered: Zoledronic acid, together with denosumab (a monoclonal antibody against the receptor activator of nuclear factor kappa B ligand), is the most frequent approach for the …

OncologyMalemedicine.medical_specialtySettore MED/06 - Oncologia MedicaClinical BiochemistryAntineoplastic AgentsBone NeoplasmsAntibodies Monoclonal HumanizedZoledronic AcidMetastasisProstate cancerBreast cancerInternal medicineDrug DiscoverymedicineAnimalsHumansMolecular Targeted TherapyBiologyPharmacologyDiphosphonatesbusiness.industrybone metastasis breast cancer denosumab prostate cancer skeletal-related events solid tumorsRANK LigandImidazolesBone metastasismedicine.diseaseSurgeryZoledronic acidDenosumabTreatment OutcomeMonoclonalPractice Guidelines as TopicHuman medicineDenosumabbusinessRANKL InhibitorEngineering sciences. Technologymedicine.drugExpert opinion on biological therapy
researchProduct

Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular ca…

2013

Locoregional therapy (LRT) is being increasingly used for the management of hepatocellular cancer (HCC) in patients listed for liver transplantation (LT). Although several selection criteria have been developed, stratifications of survival according to the pathology of explanted livers and pre-LT LRT are lacking. Radiological progression according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) and alpha-fetoprotein (AFP) behavior was reviewed for 306 patients within the Milan criteria (MC-IN) and 116 patients outside the Milan criteria (MC-OUT) who underwent LRT and LT between January 1999 and March 2010. A prospectively collected database originating from 6 collabor…

OncologyTransplantationmedicine.medical_specialtyHepatologybusiness.industrymedicine.medical_treatmentMilan criteriaLiver transplantationmedicine.diseaseSurgeryTransplantationResponse Evaluation Criteria in Solid TumorsTumor progressionInternal medicineCarcinomaMedicineSurgeryRisk factorbusinessProspective cohort studyLiver Transplantation
researchProduct

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Int…

2011

The Gynecological Cancer Intergroup (GCIG) has previously reached consensus regarding the criteria that should be used in clinical trial protocols to define progression-free survival after first-line therapy as well as the criteria to define response to treatment in recurrent disease using the serum marker CA 125 and has specified the situations where these criteria should be used. However, the publications did not include detailed definitions, nor were they written to accommodate the new version of Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1) now available. Thus, we recommend that the definitions described later in detail are incorporated into clinical trial…

Oncologymedicine.medical_specialtyMEDLINEAntineoplastic AgentsDisease-Free SurvivalInternal medicinemedicineRecurrent diseaseHumansIn patientOvarian NeoplasmsClinical Trials as Topicbusiness.industryObstetrics and Gynecologymedicine.diseaseGynecological cancerResponse to treatmentSurgeryClinical trialOncologyResponse Evaluation Criteria in Solid TumorsCA-125 AntigenDisease ProgressionFemaleHuman medicineNeoplasm Recurrence LocalOvarian cancerbusiness
researchProduct

Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or me…

2019

Oncologymedicine.medical_specialtyTemozolomideSurrogate endpointbusiness.industryCancerHematologyNeutropeniamedicine.diseaseChemotherapy regimenPoly (ADP-Ribose) Polymerase Inhibitorchemistry.chemical_compoundOncologychemistryResponse Evaluation Criteria in Solid TumorsInternal medicinemedicineRucaparibbusinessmedicine.drugAnnals of Oncology
researchProduct

Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.

2012

BACKGROUND. The objective of this study was to compare the prognostic relevance of Response Evaluation Criteria in Solid Tumors (RECIST) versus Choi criteria for the assessment of response in patients with high-risk soft tissue sarcoma of the extremities or trunk wall who received preoperative chemotherapy with or without radiotherapy in a phase 3 trial. METHODS. Patients received 3 cycles of preoperative epirubicin þ ifosfamide with or without radiotherapy. The diagnostic concordance between RECIST and Choi criteria and their correlation with overall survival (OS) and freedom from progression (FFP) were evaluated in a univariate Cox regression model. RESULTS. In 243 of 321 eligible patient…

RiskCancer Researchmedicine.medical_specialtymedicine.medical_treatmentchemotherapymedicineHumansResponse Evaluation Criteria in Solid TumorsProbabilityProportional Hazards ModelsRetrospective Studiesresponse assessmentIfosfamideProportional hazards modelbusiness.industrySoft tissue sarcomachemotherapy; Choi criteria; outcome; prognosis; response assessment; Response Evaluation Criteria in Solid Tumors; sarcoma; Cancer Research; OncologySarcomamedicine.diseasePrognosisSurgeryRadiation therapyChoi criteriaOncologyResponse Evaluation Criteria in Solid TumorsoutcomeRadiologySarcomabusinessProgressive diseasemedicine.drugEpirubicinCancer
researchProduct

Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?

2022

Alterations in short-repetitive DNA sequences, known as microsatellite instability (MSI), can reflect deficiencies in Mismatch Repair (MMR) system which represents a major player in DNA integrity maintenance. The incidence of MSI-H/dMMR has been shown to be variable depending on the tumor type. Several studies confirmed that dMMR/MSI status, although less frequent than PD-L1 expression, may better predict response to immune-checkpoint inhibitors (ICIs) in patients with solid tumors. In October 2016, the FDA granted pembrolizumab as breakthrough therapy for the treatment of non-CRC, MSI-H/dMMR tumors, providing, for the first time, a tumor-agnostic indication. In the next future, the tissue-…

Settore MED/06 - Oncologia MedicaHematologyMMR deficiencyColorectal cancerMMRPD-1/PD-L1DNA Mismatch RepairTumor-agnostic therapyOncologyNeoplasmsSolid tumorsHumansMicrosatellite InstabilityImmunotherapyColorectal NeoplasmsMSI
researchProduct

PROGNOSTIC VALUE OF D-DIMER PLASMA LEVELS IN PATIENTS WITH ADVANCED SOLID TUMORS

2012

Settore MED/18 - Chirurgia GeneralePLASMAD-DIMERSOLID TUMORS
researchProduct

POTENTIAL APPLICATIONS OF LIQUID BIOPSY IN IMMUNOTHERAPY: ROLE OF EXOSOMES, MICRORNAS AND PLASMA EXPRESSION LEVELS OF IMMUNE CHECKPOINTS IN PATIENTS …

2023

liquid biopsyImmune checkpointsolid tumors
researchProduct

Pediatric oncologic endosurgery.

2017

Despite increasing popularity of minimal-invasive techniques in the pediatric population, their use in diagnosis and management of pediatric malignancy is still debated. Moreover, there is limited evidence to clarify this controversy due to low incidence of each individual type of pediatric tumor, huge diversity of the disease entity, heterogeneity of surgical technique, and lack of well-designed studies on pediatric oncologic minimal-invasive surgery. However, a rapid development of medical instruments and technologies accelerated the current trend toward less invasive surgery, including oncologic endosurgery. The aim of this article is to review current literatures about the application o…

medicine.medical_specialtyDisease entitybusiness.industryThoracoscopyMedical instrumentsLess invasive surgeryPediatric TumorEndosurgeryGeneral Medicine03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisPediatric malignancySolid tumorsmedicine030211 gastroenterology & hepatologyLaparoscopyLimited evidenceIntensive care medicinebusinessReview ArticlesChildrenPediatric populationInternational journal of surgery. Oncology
researchProduct